EUVIMEDEUVIMED entdecken
Crossref

Primary hyperparathyroidism in adults—(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society

Frances Milat, Sabashini K Ramchand, Madhuni Herath iD, Justin Gundara, Simon Harper, Stephen Farrell, Christian M Girgis, Roderick Clifton-Bligh iD, Hans G Schneider, Sunita M C De Sousa, Anthony J Gill, Jonathan Serpell und 5 weitere

Clinical Endocrinology · 2024-01 · 100 (1) · 3-18

DOI: 10.1111/cen.14659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 21.12.2021. Verfasst von Frances Milat und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Monash Health, Victoria, Australia. Hauptthemen laut MEDLINE: Hyperparathyroidism, Primary, Surgeons. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 106 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To formulate clinical consensus recommendations on the presentation, assessment, and management of primary hyperparathyroidism (PHPT) in adults.

Methods

Representatives from relevant Australian and New Zealand Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence‐informed position statement addressing nine key questions.

Results

PHPT is a biochemical diagnosis. Serum calcium should be measured in patients with suggestive symptoms, reduced bone mineral density or minimal trauma fractures, and in those with renal stones. Other indications are detailed in the manuscript. In patients with hypercalcaemia, intact parathyroid hormone, 25‐hydroxy vitamin D, phosphate, and renal function should be measured. In established PHPT, assessment of bone mineral density, vertebral fractures, urinary tract calculi/nephrocalcinosis and quantification of urinary calcium excretion is warranted. Parathyroidectomy is the only definitive treatment and is warranted for all symptomatic patients and should be considered for asymptomatic patients without contraindications to surgery and with >10 years life expectancy. In patients who do not undergo surgery, we recommend annual evaluation for disease progression. Where the diagnosis is not clear or the risk‐benefit ratio is not obvious, multidisciplinary discussion and formulation of a consensus management plan is appropriate. Genetic testing for familial hyperparathyroidism is recommended in selected patients.

Conclusions

These clinical consensus recommendations were developed to provide clinicians with contemporary guidance on the assessment and management of PHPT in adults. It is anticipated that improved health outcomes for individuals and the population will be achieved at a decreased cost to the community.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperparathyroidism, PrimarySurgeonsAdultHumansCalciumNew ZealandAustraliaParathyroid HormoneBone DensityParathyroidectomyMinerals

Stichwörter der Autor:innen

asymptomatic hyperparathyroidismbone densityhypercalcemiahyperparathyroidismparathyroid carcinomaparathyroid hormoneparathyroidectomyrenal calculi

Substanzen

CalciumParathyroid HormoneMinerals

Autor:innen und Institutionen

  • Department of Endocrinology, Monash Health, Victoria, Australia.
  • Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Victoria, Australia.
  • Department of Medicine, Nursing & Health Sciences, Monash University, Victoria, Australia.
  • Department of Endocrinology, Austin Health, Victoria, Australia.
  • Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia.
  • Department of Surgery, Redland Hospital, Metro South and Faculty of Medicine, University of Queensland, Australia.

ORCID-Profile: Madhuni Herath, Roderick Clifton-Bligh, Mathis Grossmann

Zitieren

APA

Milat, F., Ramchand, S. K., Herath, M., Gundara, J., Harper, S., Farrell, S., Girgis, C. M., Clifton-Bligh, R., Schneider, H. G., De Sousa, S. M. C., Gill, A. J., Serpell, J., Taubman, K., Christie, J., Carroll, R. W., Miller, J. A., & Grossmann, M. (2024). Primary hyperparathyroidism in adults—(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society. Clinical Endocrinology, 100(1), 3-18. https://doi.org/10.1111/cen.14659

Vancouver

Milat F, Ramchand SK, Herath M, Gundara J, Harper S, Farrell S, et al. Primary hyperparathyroidism in adults—(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society. Clinical Endocrinology. 2024;100(1):3-18. doi:10.1111/cen.14659

BibTeX
@article{Milat2024,
  author = {Milat, Frances and Ramchand, Sabashini K and Herath, Madhuni and Gundara, Justin and Harper, Simon and Farrell, Stephen and Girgis, Christian M and Clifton-Bligh, Roderick and Schneider, Hans G and De Sousa, Sunita M C and Gill, Anthony J and Serpell, Jonathan and Taubman, Kim and Christie, James and Carroll, Richard W and Miller, Julie A and Grossmann, Mathis},
  title = {Primary hyperparathyroidism in adults—(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society},
  journal = {Clinical Endocrinology},
  year = {2024},
  volume = {100},
  number = {1},
  pages = {3--18},
  doi = {10.1111/cen.14659}
}
Kostenlos starten →